This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

WT1 Antigen Specific Cancer Immunotherapeutic (ASCI)

GlaxoSmithKline plc

Drug Names(s): GSK2302024A

Description: WT1 ASCI is a novel cancer immunotherapy (therapeutic vaccination) based on the Wilm's tumor protein 1 (WT1) gene. Wilms' tumor protein 1 (WT1) is a transcription factor involved in tumor cell proliferation. The gene encoding WT1 is overexpressed in a variety of malignant tumors. GSK’s Antigen Specific Cancer Immunotherapeutics (ASCIs) represent a class of novel compounds that are based on tumor antigens presented to the patient’s immune system as recombinant proteins in combination with a GSK proprietary adjuvant system. ASCIs are meant to trigger a specific immune response against tumor cells expressing these proteins, rallying antibodies and T-cells to recognize and attack the cancer cells in a highly specific manner and eventually eliminate them.

WT1 Antigen Specific Cancer Immunotherapeutic (ASCI) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug